HC Wainwright Reiterates “Buy” Rating for Valneva (NASDAQ:VALN)

HC Wainwright reaffirmed their buy rating on shares of Valneva (NASDAQ:VALN) in a research report sent to investors on Monday, Benzinga reports. They currently have a $26.00 price target on the stock. HC Wainwright also issued estimates for Valneva’s Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($0.50) EPS and FY2026 earnings at ($0.76) EPS.

Valneva Stock Performance

NASDAQ:VALN opened at $7.26 on Monday. The company has a market cap of $505.24 million, a price-to-earnings ratio of -17.69 and a beta of 2.20. Valneva has a 1 year low of $6.58 and a 1 year high of $15.29. The stock’s 50 day simple moving average is $7.80 and its two-hundred day simple moving average is $7.92. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.64 and a quick ratio of 2.22.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.12. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. The company had revenue of $35.56 million for the quarter, compared to analysts’ expectations of $95.80 million. As a group, equities analysts anticipate that Valneva will post -0.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. boosted its stake in shares of Valneva SE (NASDAQ:VALN) by 2.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the period. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.